Ron Evans steals a trick from I/O, and points the way to a transformational diabetes therapy

Jason Mast

Editor

Salk Institute scientist and serial biotech entrepreneur Ron Evans showed new mouse work yesterday that could point to a long-sought holy grail for diabetes treatment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ron Evans steals a trick from I/O, and points the way to a transformational diabetes therapy

Jason Mast

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Trump blog: Top HHS spokesperson resigns within weeks of being sworn in

ICER finds GSK inhalers offer advantages over generic competitors

Biohaven’s ion channel drug fails pivotal bipolar mania study

Pliant calls it quits on Phase 2b idiopathic pulmonary fibrosis study

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

Ron Evans steals a trick from I/O, and points the way to a trans­for­ma­tion­al di­a­betes ther­a­py

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Ron Evans steals a trick from I/O, and points the way to a transformational diabetes therapy